AlzChem Group Balance Sheet Health
Financial Health criteria checks 6/6
AlzChem Group has a total shareholder equity of €192.5M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €480.2M and €287.7M respectively. AlzChem Group's EBIT is €74.1M making its interest coverage ratio 28.2. It has cash and short-term investments of €40.6M.
Key information
0%
Debt to equity ratio
€0
Debt
| Interest coverage ratio | 28.2x |
| Cash | €40.62m |
| Equity | €192.49m |
| Total liabilities | €287.70m |
| Total assets | €480.18m |
Recent financial health updates
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07
Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11Recent updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Financial Position Analysis
Short Term Liabilities: ACT's short term assets (€266.2M) exceed its short term liabilities (€114.6M).
Long Term Liabilities: ACT's short term assets (€266.2M) exceed its long term liabilities (€173.1M).
Debt to Equity History and Analysis
Debt Level: ACT is debt free.
Reducing Debt: ACT had no debt 5 years ago.
Debt Coverage: ACT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ACT has no debt, therefore coverage of interest payments is not a concern.